- Headquarters
- Lund
- Founded
- 2018
- Business Model
- B2B
- Website
- asgardthx.com
- Total Funding
- $39.7M
- Last Round
- $32.8M Series AMar 2024
- Rounds
- 2
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 2 funding rounds and 5 investors for this company. The full record is or through the API.
About
Asgard Therapeutics explores direct cell reprogramming technologies to develop cancer immunotherapies. The Swedish private biotechnology business focuses its therapeutic development work on applying cell reprogramming technology to cancer immunotherapy, bringing these areas together in its research activities.
Summary
It has raised $39.7M in total across 2 rounds, most recently a $32.8M Series A round in Mar 2024. Investors include Novo Holdings A/S, Boehringer Ingelheim Venture Fund and Industrifonden.
Tech & App Stack
3 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Mar 2024
Sign up to see all 2 events
Funding: Seed through Series A. Amounts, valuations, and investors where available.
Investors
Similar Companies
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...
Novel bicyclic peptides and drug conjugates for cancer
China's leading blood products manufacturer
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/asgard-therapeutics"><img src="https://indexed.vc/api/badge/company/asgard-therapeutics" alt="Asgard Therapeutics on Indexed.vc" width="260" height="76" /></a>